

The Value of HES for Co-Morbidity Analysis

James Thomas Database Manager, Research Group Northern and Yorkshire Cancer Registry and Information Service





Collaborators



- Henrik Møller, Neil Hanchett, Jason Hiscox, Steve Richards – Thames Cancer Registry
- David Forman, Eva Morris -NYCRIS
- Chris Carrigan, Jon Shelton, Michael Chapman – National Cancer Intelligence Network
- Michel Coleman, Libby Ellis, Laura Woods, Bernard Rachet – London School Hygiene and Tropical Medicine Northern & Yorkshire

Cancer Registry & Information Service

Northern and Yorkshire Cancer Registry and Information Service

NHS



Using information to improve quality & choice





- Background to National Cancer Data Repository
- Charlson Calculations Approaches and Issues
- Analysis Results

Background




- National Cancer Data Repository has been in existence for ~2yrs
 - ONS Minimum Cancer Dataset (1971-2006 / 9239786 tumours)
 - Merged Registry Dataset (1990-2006 / 5286574 tumours)
 - Containing Additional tumour and treatment information
 - Inpatient Hospital Episode Statistics Data (1997-2007 / 33 million episodes / 4.9 million patients)
- Linkage rate of ~ 80% in latest years
- Additional datasets linked into NCDR
 - Colorectal Screening Data
 - General Practice Research Database
- Planned Linkages
 - Outpatient HES
 - NCASP data
 - Rapid HES

Background

- NCIN intended the NCDR to be used to monitor processes and outcomes of care
- Levels of co-morbidity influence care so important to quantify but limited information makes this difficult
- Charlson score developed to quantify comorbidity from routine data
- Standard scoring system that is widely used

Methods to Calculate Charlson from MHS NCDR

- HES Episodes Diagnosis recorded in 14 DIAG Fields
- Time periods assessed prior to diagnosis
 1yr / 2yr / Anytime
- Charlson ICD10 codes looked up across all episodes in time period Not codes for tumour of interest
- Matched ICD10 codes grouped into Charlson Groups
- For NCDR Charlson groups matched to avoid double counting Severe Diabetes complications counted over Diabetes Complications
- Scores from each group summed to give a final score



Complications




- Score is very dependent on date of cancer diagnosis
 - Differences in registration processes between registries
- Cancer diagnosis is often first in-patient episode
 - Only including episodes prior to diagnosis may miss co-morbidity codes
- Coding of Cancers differ in Registry/HES Meaning cancers can be counted twice
 - e.g. an individuals colorectal tumour could be coded as C18 in registry and C19 in HES, this could lead to
- Suspected cancer diagnosis coded in HES
 - 100% over-reporting of cancer diagnosis in HES
- Cancers and Metastatic Cancer make up main proportion of scores
 - Should any cancer information be used in the calculation of the score for cancer purposes.
 - Would it be better to use definitive data on multiple tumours/mets

Results




- 3,383,871Tumours in ONS Data post 1996
- 2,644, 157 Tumours match into HES post 1996
- 382,891 (14.5%) have Charlson Score 1yr previous to diagnosis (mean = 1.62)
- 433287 (16.3%) have Charlson Score 2yr previous to diagnosis (mean = 1.67)
- 519327 (19.6%) have Charlson Score any time previous to diagnosis (mean = 1.76)

Colorectal survival by Charlson Score MHS



Rectal Tumours - Surgical Procedures by Charlson Score





□ Hartmanns □ Other □ APE ■ AR

Conclusions



- NCDR has Charlson score available at individual tumour level
- Analysis needs to be undertaken to assess the best approach to calculating comorbidity from data we have available
- We can change the way we calculate/sources of data used to calculate Charlson
- Other better indices available?